Sanofi’s Lemtrada gets support from FDA advisory panel

14 November 2013

French drug major Sanofi (Euronext: SAN) has received support from a US Food and Drug Administration advisory panel for its multiple sclerosis drug Lemtrada (alemtuzumab).

The FDA Peripheral and Central Nervous System Drugs Advisory Committee met yesterday (November 13) to discuss Lemtrada. The panel voted 17-0 with one abstention to recommend approval of the drug, according to reports.

However, some panel members were concerned at the drug’s safety. In clinical development it was found that serious autoimmune conditions can occur in patients receiving Lemtrada, but the company said a comprehensive risk management program will support early detection and management of these autoimmune events.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK